ADAG (ADAG) Stock Price & Analysis
ADAG (ADAG) fell 2.98% to USD 3.58 as of September 8, 2026 at 07:34 UTC, according to Nexqual real-time market data.
ADAG last closed at USD 3.69; the session ranged USD 3.56–3.69 on volume of 28,194 shares. Market capitalization is $240.37M, with a 52-week range of USD 1.3–4.85 (NGM). Source: Nexqual, September 8, 2026 at 07:34 UTC.
Key Statistics (as of September 8, 2026 at 07:34 UTC)
| Price | USD 3.58 |
|---|---|
| Change | ▼ 2.98% (down) |
| Previous Close | USD 3.69 |
| Open | USD 3.67 |
| Day Range | USD 3.56 – 3.69 |
| 52-Week Range | USD 1.3 – 4.85 |
| Volume | 28,194 shares |
| Market Cap | $240.37M |
| Exchange | NGM |
Technical Analysis (ADAG)
Nexqual's technical model rates ADAG "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 07:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.47 (neutral) |
| vs SMA50 | Below (USD 3.84) |
| MACD | -0.05 (negative) |
Analyst Ratings (ADAG)
Wall Street analysts rate ADAG "Strong Buy" based on 5 analysts, with a mean price target of USD 10.09 (range USD 7–17.45), per Nexqual as of September 8, 2026 at 07:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 10.09 |
| High Target | USD 17.45 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (ADAG)
| Revenue Estimate | $0 |
|---|
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financials & Fundamentals (ADAG)
| Total Revenue | $9.29M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -1023.92% |
| Profit Margin | -220.77% |
| ROE | -28.50% |
| Debt / Equity | 5.75 |
| Current Ratio | 5.02 |
| Total Cash | $127.91M |
| Total Debt | $6.09M |
| Free Cash Flow | $-12.16M |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Financial Health Score (ADAG)
Nexqual rates ADAG's overall financial health "Weak" across five dimensions, as of September 8, 2026 at 07:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $128M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Critical — ROE -29%, ROA -14.0% |
Ownership (ADAG)
| Insider Ownership | +11.36% |
|---|---|
| Institutional Ownership | +35.94% |
| Shares Outstanding | 67.14M |
| Float | 42.20M |
| Short % of Float | +3.69% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Leadership (ADAG)
ADAG is led by Peter P. Luo (age 59), Co- Founder, Chairman, CEO and President of R & D, per Nexqual as of September 8, 2026 at 07:34 UTC.
| Co- Founder, Chairman, CEO and President of R & D | Peter P. Luo (age 59) |
|---|---|
| CFO & Director | Man Kin Tam (age 48) |
| Executive Director & Head of Human Resources | Ling Zhou |
| Chief Strategy Officer | Mickael Chane-Du |
| Executive Director of Finance | Chunfang Gu |
Major Backers & Investors (ADAG)
Notable institutional backers of ADAG include Jupiter Topco LLC, Siren, L.L.C., Deerfield Management Company, L.P, according to Nexqual as of September 8, 2026 at 07:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 9.93% |
| Siren, L.L.C. | 3.97% |
| Deerfield Management Company, L.P | 3.97% |
| Ameriprise Financial, Inc. | 2.56% |
| HSG Holding Ltd | 2% |
| Squadron Capital Management LLC | 1.86% |
| Dauntless Investment Group, LLC | 0.8% |
| Citadel | 0.76% |
Source: Nexqual, September 8, 2026 at 07:34 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CNTB | Connect Biopharma Holdings Limi | USD 1.84 | ▼ 33.33% |
| ALGS | Aligos Therapeutics, Inc. | USD 6.21 | ▲ 0% |
| PHVS | Pharvaris N.V. | USD 35.25 | ▲ 0.23% |
| FTH | Faeth Therapeutics, Inc. | USD 40.05 | ▲ 2.38% |
| ANEB | Anebulo Pharmaceuticals Inc | USD 0.36 | ▲ 19.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:34 UTC. This page is informational and not investment advice.